New Analyses Allow Restart Of Ipsen's Palovarotene Clinical Program
FDA's Partial Clinical Hold For Patients Under 14 Remains
Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.
You may also be interested in...
Despite concerns over toxicity due to early growth plate closure in skeletally immature patients, Ipsen's CEO David Loew is confident that palovarotene will get through regulatory review for fibrodysplasia ossificans progressive.
Sanofi Pasteur head David Loew has been at the heart of the company's bids to develop vaccines for COVID-19 but has decided to accept a different challenge instead and take the helm at Ipsen.
Buying Canada-based Clementia is consistent with Ipsen’s strategy to acquire top assets in mid to late stages of development for specialty oncology, neuroscience or rare disease indications, chief commercial officer tells Scrip.